Science Corporation, a leading innovator in brain-computer interface (BCI) technology, has recently acquired the IP and related assets of the Pixium Vision Prima implant. This cutting-edge technology provides a potential solution for individuals suffering from blindness by acting as a photovoltaic substitute for photoreceptors, simultaneously using central prosthetic and peripheral natural vision. The Prima System was designed specifically for patients with atrophic dry age-related macular degeneration (AMD), offering a miniaturized, wireless, subretinal implant paired with a pocket computer and glasses.
Neuralink co-founder Max Hodak, who founded Science Corporation, expressed excitement about the acquisition and the opportunity it presents for developing BCI technology for vision restoration. The acquisition also ensures continuity for patients enrolled in Pixium Vision’s clinical trials, as Science is now able to provide a future for the program and further advance innovative products using different modalities.
Pixium Vision had been seeking a potential buyer for its technology, and with Science stepping in to acquire the Prima implant technology, there is a sense of relief among company leadership. Outgoing Pixium CEO Lloyd Diamond expressed confidence in Science’s ability to continue the development and commercialization of the Prima System, stating that it now has a home with a team dedicated to helping patients.
The acquisition of the Prima System adds to Science’s already impressive IP portfolio and represents a significant step forward in the company’s mission to develop cutting-edge BCI technology. The deal was finalized after Pixium went into liquidation but has been approved by the Paris Commercial Court. While the terms of the acquisition were not disclosed, both companies are looking forward to the potential impact of this collaboration on the field of vision restoration and the lives of individuals affected by blindness.
Science Corporation’s acquisition of Pixium Vision’s IP and related assets marks an important milestone in its ongoing efforts to develop advanced BCI technologies that can help restore vision to those affected by blindness or other visual impairments. With its expertise in neural interfaces and artificial intelligence, Science is well positioned to take advantage of this breakthrough technology and continue advancing innovation in this field.
As CEO Diamond stated: “We are thrilled that our work will continue under such capable hands at Science Corporation. Their commitment to helping patients regain their sight is truly inspiring.” For its part, Science Corporation remains committed to continuing research on this groundbreaking technology while ensuring that patients receive access to innovative solutions that can improve their quality of life.
Overall, this acquisition signifies an exciting new chapter in science fiction becoming science fact – restoring sight through advanced technological means such as BCI systems like Prima implants. With continued innovation from companies like Science Corporation working tirelessly towards finding solutions for those affected by blindness or other visual impairments, hope continues to grow that one day we may all see clearly once again.
